Contingent payment obligations to noteholders
Company: Core Scientific
The claim, verbatim
Convertible noteholders are eligible for up to $130 million in cash or stock over 3 years (up to ~$43 million per year) if new shares trade below plan equity value.
Source (primary)
core-scientific 8-K exhibit (d661343dex992.htm) (SEC EDGAR (8-K Ex), press_release)
View cached copy (2026-11-13)Live source ↗
Quote: “up to $130 million of potential Contingent Payment Obligations to the convertible noteholders (up to ~$43 million per year for 3 years)”
How we checked this
Checked on November 16, 2026. The cited source supports every part of this claim.
The document describes up to $130 million of contingent payments to convertible noteholders, up to about $43 million per year for 3 years, in cash or stock. It says these apply in the event the new common shares trade below the plan equity value.
Confirmed in the source:
- Convertible noteholders are eligible for up to $130 million in total
- The payments may be in cash or stock
- The payments run over a 3-year period, at up to about $43 million per year
- The payments are triggered if the new common shares trade below the plan equity value
What we did: Read our cached copy of SEC EDGAR (8-K Ex) (https://www.sec.gov/Archives/edgar/data/1839341/000119312524013078/d661343dex992.htm) in full (29,830 characters, retrieved November 13, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms core-scientific 8-K exhibit (d661343dex992.htm)
Quote: “up to $130 million of potential Contingent Payment Obligations to the convertible noteholders (up to ~$43 million per year for 3 years)”